RNS Number:1561H
Arthro Kinetics plc
07 November 2007


                                       


Press Release



             Radio Frequency system receives 510(k) US FDA approval



WEDNESDAY, 7th November 2007 - Arthro Kinetics plc (AIM: AKI) ("Arthro
Kinetics"), the orthopedics company dedicated to regenerating joint mobility and
spinal disc function announces that its VESALIUS(R) radio frequency generator
and spinal probe system for soft tissue ablation has received 510(k) approval
from the US Food & Drugs Administration (FDA).


The Arthro Kinetics radio frequency generator and spinal probe system utilizes
the VESALIUS(R) molecular resonance technology allowing the spine surgeon to
easily, accurately and efficiently cut, ablate and seal soft tissue at lower
temperatures minimizing the potential for bleeding, scarring and other damage to
surrounding tissue.


Jason Loveridge, CEO of Arthro Kinetics commented:


"This is excellent news for Arthro Kinetics. Radio frequency technology is a
critical component of endoscopic surgery and this approval enhances
significantly the portfolio of instruments we can now make available to surgeons
in the US".


CONTACTS

Arthro Kinetics Plc                              Tel: +49 (0)711 305 110 70
Jason Loveridge, Chief Executive Officer
Doug Quinn, Chief Financial Officer

Nomura Code Securities Limited                   Tel: +44 (0)207 776 1200
Clare Terlouw


END



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
REAUNUWRBWRARAA
Arthro Kinetics (LSE:AKI)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Arthro Kinetics Charts.
Arthro Kinetics (LSE:AKI)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Arthro Kinetics Charts.